CN1234373C - Medicinal preparation containing lactobacillus acidophilus and preparation process thereof - Google Patents
Medicinal preparation containing lactobacillus acidophilus and preparation process thereof Download PDFInfo
- Publication number
- CN1234373C CN1234373C CNB001254693A CN00125469A CN1234373C CN 1234373 C CN1234373 C CN 1234373C CN B001254693 A CNB001254693 A CN B001254693A CN 00125469 A CN00125469 A CN 00125469A CN 1234373 C CN1234373 C CN 1234373C
- Authority
- CN
- China
- Prior art keywords
- bacillus acidophilus
- preparation
- vagina
- strain
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 240000001046 Lactobacillus acidophilus Species 0.000 title claims abstract description 86
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 title claims abstract description 84
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 229940039695 lactobacillus acidophilus Drugs 0.000 title abstract description 7
- 210000001215 vagina Anatomy 0.000 claims abstract description 84
- 239000007788 liquid Substances 0.000 claims abstract description 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 239000007921 spray Substances 0.000 claims abstract description 7
- 239000007787 solid Substances 0.000 claims abstract description 6
- 239000006071 cream Substances 0.000 claims abstract description 3
- 239000000829 suppository Substances 0.000 claims abstract description 3
- 241000894006 Bacteria Species 0.000 claims description 60
- 230000001580 bacterial effect Effects 0.000 claims description 21
- 229920001817 Agar Polymers 0.000 claims description 13
- 239000008272 agar Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000003826 tablet Substances 0.000 claims description 12
- 238000000855 fermentation Methods 0.000 claims description 11
- 230000004151 fermentation Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 210000003756 cervix mucus Anatomy 0.000 claims description 7
- 239000002609 medium Substances 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 5
- 235000015193 tomato juice Nutrition 0.000 claims description 5
- 201000000077 Cysticercosis Diseases 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 208000004441 taeniasis Diseases 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 235000015278 beef Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000013583 drug formulation Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000011081 inoculation Methods 0.000 claims description 2
- 239000002932 luster Substances 0.000 claims description 2
- 239000013521 mastic Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 206010018612 Gonorrhoea Diseases 0.000 abstract description 6
- 208000001786 gonorrhea Diseases 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 239000006072 paste Substances 0.000 abstract 1
- 208000013464 vaginal disease Diseases 0.000 abstract 1
- 241000186660 Lactobacillus Species 0.000 description 48
- 241000222122 Candida albicans Species 0.000 description 46
- 229940095731 candida albicans Drugs 0.000 description 45
- 241000588724 Escherichia coli Species 0.000 description 44
- 229940039696 lactobacillus Drugs 0.000 description 43
- 238000012360 testing method Methods 0.000 description 34
- 241000700159 Rattus Species 0.000 description 33
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000007938 effervescent tablet Substances 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 239000000853 adhesive Substances 0.000 description 16
- 230000001070 adhesive effect Effects 0.000 description 16
- 230000000844 anti-bacterial effect Effects 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 210000002919 epithelial cell Anatomy 0.000 description 12
- 241000588653 Neisseria Species 0.000 description 11
- 244000052616 bacterial pathogen Species 0.000 description 11
- 239000004310 lactic acid Substances 0.000 description 11
- 235000014655 lactic acid Nutrition 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 206010046914 Vaginal infection Diseases 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000000981 epithelium Anatomy 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- 241000251468 Actinopterygii Species 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 238000005842 biochemical reaction Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 4
- 235000011613 Pinus brutia Nutrition 0.000 description 4
- 241000018646 Pinus brutia Species 0.000 description 4
- 241000219000 Populus Species 0.000 description 4
- 240000000111 Saccharum officinarum Species 0.000 description 4
- 235000007201 Saccharum officinarum Nutrition 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 201000008100 Vaginitis Diseases 0.000 description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 description 4
- 235000012333 Vitis X labruscana Nutrition 0.000 description 4
- 240000006365 Vitis vinifera Species 0.000 description 4
- 235000014787 Vitis vinifera Nutrition 0.000 description 4
- 229960004821 amikacin Drugs 0.000 description 4
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 150000003851 azoles Chemical class 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 229960001668 cefuroxime Drugs 0.000 description 4
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 150000002016 disaccharides Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 4
- 229960001625 furazolidone Drugs 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 238000010562 histological examination Methods 0.000 description 4
- 235000012907 honey Nutrition 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 239000006152 selective media Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- 102000040350 B family Human genes 0.000 description 2
- 108091072128 B family Proteins 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 2
- 241000186869 Lactobacillus salivarius Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 239000005030 aluminium foil Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XWBADQOPXPRKBX-FMIVXFBMSA-N 1-n,1-n-diethyl-4-n-[6-methoxy-2-[(e)-2-(4-nitrophenyl)ethenyl]quinolin-4-yl]pentane-1,4-diamine Chemical compound N=1C2=CC=C(OC)C=C2C(NC(C)CCCN(CC)CC)=CC=1\C=C\C1=CC=C([N+]([O-])=O)C=C1 XWBADQOPXPRKBX-FMIVXFBMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000269799 Perca fluviatilis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003716 antitrichomonal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229940060243 calcium carbonate 60 mg Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000004956 cell adhesive effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- -1 lanoline Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a medicinal preparation containing lactobacillus acidophilus, which is prepared from the lactobacillus acidophilus and a medicinal excipient. The preparation of the present invention is liquid, solid, cream, emulsifiable paste, suppositories or spray. The preparation can be used for treating and preventing vagina diseases, vagina infection, gonorrhea, etc.
Description
The present invention relates to biological preparation, be specifically related to a kind of bacillus acidophilus's of containing pharmaceutical preparation and preparation method.
Parasitize normal intravaginal micropopulation and mainly contain antibacterial, fungus, protozoon and virus.Secondly their main perch are cervix uteri in the gauffer and the fornix portion of mucosa.Main permanent bacterium has in intravaginal: lactobacillus, staphylococcus epidermidis, escherichia coli, corynebacterium, B family streptococcus, streptococcus faecalis, mycoplasma, Candida albicans, dyspepsiacoccus and bacteroid etc.General record with quantitative methods with qualitative that viable bacteria is 10 in the healthy women vaginal discharge
2CFU/ml-10
9CFU/ml, anaerobe is 5: 1 with the ratio of aerobe, wherein lactobacillus is the permanent bacterium most important in the vagina normal flora, that quantity is maximum.Lactobacillus accounts for more than 95% of all permanent bacterium of intravaginal under the normal condition, is normal flora, contain in the every approximately ml vaginal secretions of its amount≤10
4CFU.Studies show that at present from the healthy women intravaginal is separable and go out 16 kinds of lactobacilluss, separation rate reaches 50-80%, wherein a fairly large number of is bacillus acidophilus's (77.5%), Lactobacillus salivarius and Lactobacillus fermenti, and the strong bacterium of glycogen capacity of decomposition comprises bacillus acidophilus, Lai Shi lactobacillus and Lactobacillus salivarius.Lactobacillus plays an important role in keeping the microecology in vaginas balance.It can decompose the glycogen in the vaginal mucosa epithelial cell, produces a certain amount of lactic acid and then keeps the lower acid-base value of intravaginal, makes vagina keep sour environment, suppresses the undue growth of harmful bacterium, helps the self purification of vagina.It can improve body's immunological function simultaneously, and activating macrophage is kept the partial anti-infection ability of vagina.
Vaginal secretions can not gathered in heapsly when the gynecological specula was checked, polymorphonuclear neutrophil leukocyte is wherein seldom arranged, and the vaginal secretions smear is through Gram, and the epithelial cell sharpness of border has the darker Gram-positive lactobacillus of volume dyeing in the smear.Vaginal wall exists a large amount of lactobacilluss can form a kind of biomembrane, has played the occupancy protective effect.The bacillus acidophilus is one of normal flora bacterial strain of superiority bacteria spp in the healthy women intravaginal micropopulation, and quantity is maximum, accounts for 67% of whole flora.They play balanced action to normal flora, make host's microecology in vaginas system be in dynamic equilibrium, keep the woman vagina normal function, avoid being had the invasion and attack of bacterium or exogenous pathogenic bacterium of dwelling in pathogenic.
The vaginitis morbidity is relevant with the microecology in vaginas environment change: the rising of (1) vagina pH value; (2) variation of gonadal hormone in the menstrual cycle; (3) vagina lavation, the improper vagina part that makes of lavation is injured; Also suppressed the vagina normal flora when (4) pathogenic bacteria has been killed in application such as antibiotic; (5) simultaneously with other infection.Under the systemic disease, vagina local damage, ovarian function or mistakes degree uses such as immunosuppressant, antitumor drug all cause in the vaginal microbial flora some permanent bacterium to be taken advantage of a weak point, cause vaginal infection.The main source that infects be among the vagina microorganism group many potentiality pathogenic microorganism such as escherichia coli, bacteroid, dyspepsiacoccus, staphylococcus aureus, B family streptococcus, Candida albicans, trichomonacide, mycoplasma etc.More than 5 kinds of situations can destroy the microecological balance of vagina, cause the pathogenic bacterium breeding and cause vaginitis.In addition, the anaerobe breeding while, some Ammonia material produces, and the vagina that also further alkalizes comes off vagina epithelium, and vaginal secretions is unusual.And some Ammonia material also can further promote the anaerobe growth to increase the weight of colpitic symptom, causes the microecology in vaginas environmental disruption.Vaginitis is one of common, multiple disease of women, and is relevant with microecological balance in the woman vagina.Nearly more than ten years are because the progress of vagina microorganism fundamental research, for the development and application of this class preparation provides scientific basis.
The preparation that contains lactobacillus, the killed bacterial cell that causes owing to the physical impacts that produces in preparation accounts for certain proportion, and when they when further diffusion and their breeding begin in vaginal canal, the quantity of bacterial cell further reduces, and therefore, needs to handle the suitable kind of lactobacillus, or adjuvant, with the preparation that comprises them, to guarantee preparation good quality is arranged, it is real useful using to patient.In addition, preparation should be able to keep the bacillus acidophilus's that breeds quantity constant, and guarantees bacillus acidophilus's effect unchangeably continuously when the vaginal canal internal diffusion.
The applicant has found to obtain the pharmaceutical preparation for the basis to the very effective bacillus acidophilus of treatment vaginal infection, it provides following feature, can satisfy possible top level: (1) selected strain of lactobacillus acidophilus must have the high-affinity of pair vagina epithelium, promptly adhere to the high-performance of vaginal epithelial cell, this performance can interact antibacterial with vaginal mucosa under physiology and pathological conditions, execution is in the competition effect of epithelium acceptor site and pathogenetic organism, and reconstruction microorganism system and optimum pH condition.(2) high interference performance must be arranged, competition escherichia coli and the adhesion of Candida albicans on human vagina's epithelial cell.(3) high-performance that suppresses escherichia coli, Candida albicans, gonococcus growth must be arranged.
Therefore, the purpose of this invention is to provide and satisfy above feature, reach the preparation of the bacillus acidophilus of possible top level, and be suitable for being used for the treatment of effectively vaginal infection, as vaginitis, gonorrhea etc. for the basis.
The invention provides a kind of bacillus acidophilus's of containing pharmaceutical preparation, said preparation is made up of bacillus acidophilus and pharmaceutical excipient.
The bacillus acidophilus that the present invention uses is the viable bacteria of making behind external artificial fermentating breeding.This strain with Tomato juice as culture medium, through external artificial fermentation, cooling, centrifugal, with protective agent after preparationization after the lyophilizing, be used for the treatment of vaginal infection, play the microecology in vaginas therapeutical effect.This strain mycopowder bacterium amount is with 10
8-10
10CFU/g is excellent, and preferred bacterium amount is approximately 10
11CFU/g.This bacillus acidophilus therapeutic dose (bacterium amount) should be greater than 10
4CFU/g, preferred bacterium amount is 10
6-10
7CFU/g.
Another object of the present invention has provided the preparation method of a kind of bacillus acidophilus's of containing pharmaceutical preparation, and this method comprises the following steps:
1, preparation bacillus acidophilus mycopowder:
The bacillus acidophilus SL9404 bacterial strain that secretions in the vagina is separated, obtains behind the purification is rule on the MRS agar slant and is gone down to posterity, and cultivates 48h through 37 ± 1 ℃.Choose full, color and luster is even, medium bacterium colony bigger than normal, once more on the MRS agar slant of streak inoculation in the Fructus Solani melongenae bottle, cultivates 48h through 37 ± 1 ℃.Transferred species inserts beef cysticercosis cellulosae cutis pipe, cultivates 20-50h for 37 ± 1 ℃.Get 1-4 and prop up the cysticercosis cellulosae cutis pipe and change 300ml milk fermentation culture medium or 5-20% Tomato juice fermentation medium or milk+Tomato juice's fermentation medium over to, cultivate the 8-48h fermentation culture for 37 ± 1 ℃, progressively be amplified to bulk fermentation, centrifugal, make mycopowder after the lyophilization;
2, preparation medicament:
Take by weighing bacillus acidophilus and pharmaceutical excipient by recipe quantity, drug formulation process is made various preparations routinely.
The preservation of this strain is excellent with cryodesiccated form.
This strain is preserved in Chinese typical culture collection center on June 12nd, 2000, is numbered CCTCC NO:M200013.
The Pro-Bionate's of the containing of the present invention mechanism of action mainly contains:
(1) keeps sour environment.Vagina living preparation of lactobacillus preparation can replenish the most important lactobacillus of patient's intravaginal, it can decompose the glycogen of storing in the vaginal mucosa epithelium and produce acidic materials such as lactic acid, acetic acid, itself also can produce lactic acid simultaneously, this plays an important role but kill multiple pathogenic microorganism to keeping the sour environment of vagina.
(2) occupy-place protective effect.Studies have shown that in a large number ectogenic lactobacillus can adhere to the vaginal mucosa epithelium securely, form spatiality occupy-place protective effect.
(3) direct antagonism.The inside and outside studies confirm that lactobacillus adds moral sodium Salmonella, infusorian, candidiasis, staphylococcus etc. to vagina direct inhibitory action is arranged.
(4) produce multiple antibacterial substance.Lactobacillus can decompose the glycogen of storing in the vaginal mucosa epithelium, produces acidic materials such as lactic acid, acetic acid, and itself also can produce lactic acid simultaneously, keeps the sour environment of vagina, but kills multiple pathogenic microorganism.
(5) nutrient competition.Be colonizated in the lactobacillus in the vagina in a large number, nutrition is in the competitive advantage state, is unfavorable for the growth of other bacterium.The lactobacillus therapy is that the living preparation of lactobacillus preparation is put in the vagina, makes living preparation of lactobacillus get back to its natural physiological function of performance in the body, adjusts vaginal microbial flora, and maintaining ecological balance makes vaginal microbial flora reach microecological balance again, reaches the purpose of disease preventing and treating.
Dosage form of the present invention can be liquid form, mastic form or solid form, as tablet, capsule, powder, cream, ointment, suppository or spray.
The described common drug excipient of preparation of the present invention comprises corn starch, pregelatinized Starch, carboxymethyl starch sodium, dextrin, lactose, isolactose, mannitol, glucose, vitamin C, citric acid, sodium dihydrogen citrate, disodium citrate, tartaric acid, fumaric acid, boric acid, acidic amino acid class weak acid such as (as: glutamic acid, aspartic acids), microcrystalline Cellulose, sodium carboxymethyl cellulose (calcium), hypromellose, polyvinylpyrrolidone, gelatin, calcium carbonate, sodium bicarbonate, magnesium stearate, lanoline, Polyethylene Glycol etc.Additive is meant relevant nutrients such as edible defatted milk powder, vitamin C, glutamic acid.
The Pro-Bionate of containing of the present invention can be used for treatment of diseases and preventions such as woman vagina infection aspect, gonorrhea.
One, the bacillus acidophilus observes (Nat'l Pharmaceutical ﹠ Biological Products Control Institute's detection) to human vaginal epithelial cell (VEC) adhesive attraction
(1) purpose: observe bacillus acidophilus SL9404 to the epithelial adhesive attraction of human vagina.
(2) materials and methods:
1, human vagina's epithelial cell (hereinafter to be referred as VEC):
Take from healthy women, the age, the hospital-based outpatient obstetrical clinic health check-up was normal below 40 years old.
Scrape the VEC specimen of getting and be suspended among the 20mlRPMI-1640 vortex mixer concussion washed cell immediately 3 times, 500rpm * 3min, filter is sucking filtration repeatedly, removes the endogenous antibacterial.The blood counting chamber counting is adjusted VEC concentration 10
5/ ml.
2, strain:
(1) separates from healthy women vagina bacillus acidophilus 9403, SL9404 and 9405 strain bacterium
(2) escherichia coli CMCC44113 strain
(3) Candida albicans CMCC 10231 strains
(4) Deshi Lactobacillus one strain separates and makes the bacterium raw product by oneself
3, bacterium liquid preparation:
Lactobacillus is inoculated in MRS culture medium, escherichia coli and Candida albicans is inoculated in ordinary nutrient agar, 37 ℃, cultivated in 18 hours; Scrape before the test and get lawn, 3 times (3000 * 10min), adjust cell concentration is 1 * 10 to RPMI-1640 washing antibacterial
8/ ml.
4, method:
(1) adherence test: 3 strain bacillus acidophilus adhesive attractions relatively
Get VEC suspension and each 1ml of bacterium liquid, mix, 37 ℃, cultivated in 2 hours; Smear, drying at room temperature, methanol is 10min fixedly, and Gram, mirror are observed antibacterial adhesion situation and counting on VEC down.
(2) lactobacillus is divided into following three groups and carries out the influence of escherichia coli, Candida albicans adhesion VEC:
First group: add 1ml Escherichia coli bacteria liquid or 1ml Candida albicans bacterium liquid in the 1ml lactobacillus bacterium liquid, add 1mlVEC suspension mixing again, 37 ℃, 2 hours, observe down and counting by above-mentioned test method mirror.
Second group: 1ml lactobacillus bacterium liquid and 1mlVEC suspension mixing, after 30min cultivates in 37 ℃ of 2 elder generation, add 1ml Escherichia coli bacteria liquid or 1ml Candida albicans bacterium liquid again, mixing continues 37 ℃, 2 hours, observes down and counting with above-mentioned test method mirror.
5, counting: count 50 VEC under the mirror at random and go up adherent bacterial population, calculate average and standard deviation.
(3) result
1, the not comparison of homophyletic bacillus acidophilus adhesive attraction:
Three strain bacillus acidophilus are different to the adhesive attraction of human body VEC, wherein the SL9404 strain has significantly adhesive attraction to VEC, see Table 1, be the bacterial adhesion number (113.8 ± 33.69) of 50 VEC, and 9403 and 9405 strains are through cultivating 37 ℃ with VEC, after 2 hours, a large amount of cell distribution are not seen obvious adhesion on VBC in mixed liquor.The contrast bacterium is promptly also not obvious by deciding the living isolating Deshi Lactobacillus adhesive attraction of bacterium.
Table one bacillus acidophilus SL9404 strain is to the adhesive attraction of VEC
| The VEC numbering | The adhesion bacterial population (individual/VEC) | The VEC numbering | The adhesion bacterial population (individual/VEC) | The VEC numbering | The adhesion bacterial population (individual/VEC) |
| 1 | 132 | 18 | 92 | 35 | 85 |
| 2 | 113 | 19 | 120 | 36 | 123 |
| 3 | 74 | 20 | 89 | 37 | 144 |
| 4 | 149 | 21 | 65 | 38 | 131 |
| 5 | 186 | 22 | 78 | 39 | 156 |
| 6 | 118 | 23 | 158 | 40 | 98 |
| 7 | 111 | 24 | 75 | 41 | 143 |
| 8 | 63 | 25 | 126 | 42 | 125 |
| 9 | 84 | 26 | 118 | 43 | 95 |
| 10 | 89 | 27 | 109 | 44 | 194 |
| 11 | 94 | 28 | 138 | 45 | 88 |
| 12 | 118 | 29 | 80 | 46 | 155 |
| 13 | 119 | 30 | 128 | 47 | 178 |
| 14 | 125 | 31 | 74 | 48 | 122 |
| 15 | 90 | 32 | 77 | 49 | 167 |
| 16 | 120 | 33 | 50 | 50 | 133 |
| 17 | 129 | 34 | 62 | X±S | 113.8±33.69 |
2, bacillus acidophilus SL9404 strain adheres to the influence of VEC to escherichia coli, Candida albicans
(1) escherichia coli 44113 strains and Candida albicans 10231, white 157.14 ± 54.06 and 31.84 ± 11.65 (seeing Table 2).
Table 2, first group of result of the test
| Bacterial strain | Escherichia coli 44113 adhesion number/VEC (X ± S) | Candida albicans 10231 adhesion number/VEC (X ± S) | Statistical disposition |
| Escherichia coli 44113 | 157.14±54.06 | ||
| Lactobacillus lactis SL9404+escherichia coli 44113 | 118.13±49.24 | P＜0.01 | |
| Deshi Lactobacillus+escherichia coli 44113 | 147.78±45.12 | P＞0.05 | |
| Candida albicans 10321 | 31.84±11.65 | ||
| Lactobacillus Acidophilus S9404+Candida albicans 10231 | 9.76±5.94 | P＜0.01 | |
| Deshi Lactobacillus+Candida albicans 10231 | 15.66±8.45 | P＜0.01 |
(2) first groups of result of the tests (table 2) are indicated, after bacillus acidophilus SL9404 strain and escherichia coli 44113 strains or Candida albicans 10231 strains are incubated at 37 ℃ simultaneously, the SL9404 strain can suppress the adhesive attraction of other two strains bacterium, statistical procedures has notable difference, and comparison is more obvious according to the inhibitory action of Deshi Lactobacillus.
(3) second groups of result of the tests show that after bacillus acidophilus's 9405 strains were at that time cultivated with VEC earlier, when adding escherichia coli 44113 or candida albicans 10231 again (table 3), then bacillus acidophilus SL9404 strain meeting obviously suppressed the effect that back two strain bacterium adhere to VEC.
Table 3, the 2nd group of result of the test
| Bacterial strain | Escherichia coli 44113 adhesion number/VEC-(X ± S) | Candida albicans 10231 adhesion number/VEC (X ± S) | Statistical disposition |
| Escherichia coli 44113 | 267.22±97.80 | P＜0.01 | |
| Bacillus acidophilus SL9404+escherichia coli 44113 | 125.26±51.64 | ||
| Candida albicans 10231 | 29.24±8.45 | P＜0.01 | |
| Bacillus acidophilus's SL9404+Candida albicans 10231 | 19.54±10.24 |
(4) the 3rd groups of result of the tests show that after escherichia coli 44113, Candida albicans 10231 were cultivated with VEC earlier, when adding bacillus acidophilus SL9404 strain again, the SL9404 strain adheres to VEC to preceding two strain bacterium also obvious suppression effect (seeing Table 4)
Table 4, bacillus acidophilus SL9404 strain influence at the VEC adhesive attraction colibacillus 44113 or Candida albicans 10231
| Bacterial strain | Escherichia coli 44113 adhesion number/VEC (X ± S) | Candida albicans 10231 adhesion number/VEC (X ± S) | Statistical disposition |
| Escherichia coli 44113 | 180.7±252.20 | P＜0.01 | |
| Escherichia coli 44113+bacillus acidophilus SL9404 | 134.18±40.63 | ||
| Candida albicans 10231 | 29.24 ±8.85 | 0.01＜P＜0.05 | |
| Candida albicans 10231+bacillus acidophilus SL9404 | 24.40±11.36 |
(4) conclusion:
1, bacillus acidophilus SL9404 strain has tangible adhesive attraction to this vaginal epithelial cell of people.
2, bacillus acidophilus SL9404 strain can suppress escherichia coli 44113 strains and Candida albicans 10231 strains at the epithelial adhesive attraction of human vagina.
3, bacillus acidophilus SL9404 strain is more obvious than separating the Deshi Lactobacillus of making the living preparation of bacterium by oneself to human vagina's epithelial cell adhesive attraction.
Two, the research of 3 kinds of pathogenic bacterium of the external antagonism of bacillus acidophilus (calibrating of Chinese biological goods is measured)
(1) purpose: observe bacillus acidophilus SL9404 external to three kinds of common vaginal pathogenic, the i.e. antagonism of Escherichia coli, gonococcus and Candida albicans.
(2) materials and methods:
(1) strain:
1. bacillus acidophilus SL9404 strain: provide by friendship Pharma Inc. of last Hisense.
2. three kinds of pathogenic bacterium provide by Chinese medicine antibacterial preservation administrative center:
Escherichia coli CMCC44113
Gonococcus (hereinafter to be referred as gonorrhea) CMCC29403
Candida albicans CMCC10231
(2) culture medium:
1. contain 2% calf serum TPY culture fluid: be used for liquid culture.
2. lactobacillus selective medium: adopt the MRS agar culture medium.
3. escherichia coli selective medium: adopt the MRS agar culture medium.
4. Candida albicans selective medium: adopt brave red agar culture medium.
5. gonorrhea selective medium: adopt the NG agar culture medium.
(3) bacterium liquid preparation:
With each bacterial strain fresh cultured thing, use standard antibacterial opacity tube than turbid respectively, and adjust bacterial concentration with 2% calf serum TPY culture fluid, the bacillus acidophilus is: 1 * 10
7/ ml, other three kinds of pathogenic bacterium are 1 * 10
5/ ml.
(4) test grouping: bacillus acidophilus bacterium liquid mixes the formation matched group respectively with three kinds of pathogenic bacterium bacterium liquid mixed in equal amounts (9ml+9ml) in triangular flask.
Test group and matched group all place 37 ℃ of aqueous solutions to be cultured to 72 hours or 96 hours.
(5) bacterium quantitative determination:
Above-mentioned each test group, matched group are being cultivated initial (), each sampling in 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, bacillus acidophilus in the determination test group triangular flask and the antibacterial production concentration of three kinds of pathogenic bacterium respectively at 0 o'clock.Also measure simultaneously the bacterium amount of each matched group.The bacterium quantity measuring method carries out with reference to the count plate method of nineteen ninety-five version " Chinese biological goods rules " regulation, and adds up into table with the logarithm value of bacterium amount concentration.
(3) result and analysis
(1) table 5 shows the antagonism of bacillus acidophilus SL8404 to three kinds of common vaginal pathogenic, show when the SL9404 strain respectively with escherichia coli, gonococcus and 72-96 hour well-grown of Candida albicans Mixed culture; Every ml viable bacteria concentration is all 1 * 10
8More than the individual bacterium: the number of viable of SL9404 strain and matched group are approximate in each test group.
(2) table 5 shows that three kinds of pathogenic bacterium are cultured to 12 hours in test group or the matched group, and viable bacteria concentration obviously increases, and two groups of bacterium amounts are close.
(3) after table 5 showed that gonorrhea bacterium in the test group was cultured to 12 hours, growth obviously suppressed, and to 24 hours, every ml bacterium liquid viable bacteria concentration was less than 10, and this moment matched group the bacterium amount still be consistent with 12 hours bacterium amount.
(4) table 5 shows matched group escherichia coli cultivation 72 hours, and the still every ml of bacterial concentration is greater than 10
8Escherichia coli are cultured to 24 hours in the test group, and viable bacteria concentration is also 10
8More than/the ml, similar to matched group, but growth obviously suppresses after 24 hours.The viable bacteria amount is lower than 10 in 48 hours every ml bacterium liquid
5
(5) table 5 has shown that also the growth of Candida albicans also has certain inhibition in the test group, and from cultivating 12 hours to 96 hours, its viable bacteria concentration is low than matched group.
Table five bacillus acidophilus SL9404 strain antagonistic effect result
| Group | Viable count (CFU/ml) the Log value of different incubation times | ||||||
| 0 hour | 12 hours | 24 hours | 48 hours | 72 hours | 96 hours | ||
| Test group | SL9404+gonococcus 29403 | 5.9165 3.3979 | 8.3502 3.8692 | 8.8209 ＜1 | 8.4983 ＜1 | 8.0253 ＜1 | |
| SL9404+escherichia coli 44113 | 5.9165 3.7782 | 8.2577 8.8727 | 8.8395 8.7404 | 8.9004 ＜5 | 8.7308 ＜1 | ||
| SL9404+Candida albicans 10231 | 5.9165 3.7782 | 8.3201 7.6821 | 8.5775 7.8420 | 8.7745 7.7474 | 8.8028 7.8921 | 8.7559 7.9731 | |
| Matched group | Gonococcus 29403 | 3.3979 | 3.8865 | 3.6990 | ＜1 | ＜1 | |
| Escherichia coli 44113 | 3.7782 | 8.8882 | 8.8176 | 8.8987 | 8.4409 | ||
| Candida albicans 10231 | 3.7782 | 7.8481 | 8.1614 | 8.1903 | 8.4314 | 8.2041 | |
| Bacillus acidophilus SL9404 | 5.9165 | 8.4100 | 8.7752 | 8.2455 | 7.8722 | 7.1303 | |
(4) conclusion:
1. bacillus acidophilus SL9404 strain can comparatively fast suppress in external growth to gonococcus.
2. bacillus acidophilus SL9404 strain is grown at the external Escherichia coli that suppresses.
3. bacillus acidophilus SL9404 strain has certain effect external to Candida albicans.
Three, vagina with the lactobacillus effervescent tablet to rat vagina irritant test (Chinese Academy of Sciences's Shanghai medicine is measured)
24 of female sd inbred rats are divided into 3 groups, administration group, vehicle group and untreated fish group, 8 every group.Continuous 7 days vagina administrations are whenever in observation behavior and external genital situation.Getting rat vagina in 24 hours after the last administration organizes macroscopy and does the pathology histological examination.Experimental result shows, the perusal tangible abnormal response of pudendum of not regarding sb. as an outsider, and histopathologic examination does not have obvious pathological changes.
1, experiment purpose:
Observe vagina with continuous 7 days rat vagina administrations of lactobacillus effervescent tablet after irritant reaction.
2, be subjected to the reagent thing:
(1) title: vagina lactobacillus effervescent tablet, white olive-shaped tablet.
(2) specification: 1.7 * 10
7CFU/ sheet (0.25g/ sheet)
(3) unit of providing: Shanghai Xinyi Pharmaceutical Co., Ltd
(4) lot number: DM-03257
3, tester:
(1) excipient: the 0.25g/ sheet, Shanghai Xinyi Pharmaceutical Co., Ltd provides.
(2) lot number: DM03250
4, animal:
(1) give processing before source, kind, the strain test: 24 of female sd inbred rats are provided by Chinese Academy of Sciences's Shanghai Experimental Animal Center.The quality certification: No. the 005th, the moving pipe of middle section.Single cage is raised, and animal freely ingests, drinking-water.Raise a week at institute of materia medica, Chinese Academy of Sciences Shanghai Animal House before the experiment.
(2) body weight 242 ± 24g
(3) sex: female
(4) every treated animal thing: be divided into 3 groups at random by body weight, 8 every group, promptly tried thing group, excipient and untreated fish group.
(5) Animal House temperature: 23 ± 2 ℃
5, dosage
(1) dosage setting: clinical human vagina lactobacillus effervescent tablet 10
6CFU/ sheet/people.The rat dosage is decided to be 1.7 * 10
7The CFU/ sheet/only.Local application's amount is about 10 times of human dosage.
(2) every animals administer capacity: the 0.25g/ sheet/only.
6, route of administration
The rat vagina administration
7, method
To be tried thing during test and be inserted gently in the rat vagina, be guaranteed that medicine contacts until dissolving with vaginal mucosa looking on to examine.Once a day, each a slice continuous 7 days, is observed rat behavior and external genital situation every day.Dissected in 24 hours after the last administration and carry out macroscopy and draw materials and make histology's microscopy.
8, observation index
(1) perusal: observe rat behavior reaction, vaginal orifice situation every day.After the last administration, put to death rat in 24 hours, take out vagina tissue, observe stimulation phenomenons such as having or not hyperemia, redness.
(2) histological examination: every rat vagina sample of tissue is done the pathology histological examination.
(3) result judges: result of the test and untreated fish group compare judgement.
9, result:
(1) perusal: after the rat administration in continuous 7 days behavior normal, perusal external genital Non Apparent Abnormality reaction.After the last administration 24 hours, take out vagina tissue, do not see that hyperemia, redness etc. stimulate phenomenon.
(2) histological examination: histopathology is observed vagina epithelium and is stratified squamous epithelium, and structure is normal, there is no ANOMALOUS VARIATIONS.
10, conclusion:
Vagina lactobacillus effervescent tablet 1.7 * 10
7CFU/ sheet/only continuous 7 days, perusal rat vagina Non Apparent Abnormality reaction after the administration, histopathologic examination also no abnormality seen changes.The vagina lactobacillus effervescent tablet reaction non-stimulated to rat vagina.
Four, rat vagina is with lactobacillus effervescent tablet mtd test (being measured by Chinese Academy of Sciences's medicine)
24 of female sd inbred rats are divided into 4 groups.Test vagina and give the acute toxicity of lactobacillus effervescent tablet.Dosage is 1.7 * 10
7, 6.9 * 10
9The CFU/ sheet/only, other establishes vehicle group and untreated fish group, totally 4 dosage groups.Observed behavior in continuous 14 days reaction and record body weight gain situation.Activities in rats is normal after the administration, and Non Apparent Abnormality changes, no animal dead.Dissected all animals on the 15th day, the macroscopy internal organs are not seen obvious pathological changes.Rat is to lactobacillus effervescent tablet maximum tolerated dose＞6.9 * 10
9DFU/ only.Calculate by absolute magnitude, be people's consumption 10
6More than 1000 times of CFU/ sheet/people.
1, experiment purpose:
Observe rat vagina and once contact the influence that is tried the acute toxic reaction, death condition and the body weight that are produced behind the thing.
2, be subjected to the reagent thing:
(1) title: vagina lactobacillus effervescent tablet, white olive-shaped tablet.
(2) specification: 1.7 * 10
7, 6.9 * 10
9CFU/ sheet (0.25g/ sheet)
(3) unit of providing: Shanghai Xinyi Pharmaceutical Co., Ltd
(4) lot number: DM-03257; DM-03255
3, tester:
(1) excipient: the 0.25g/ sheet, Shanghai Xinyi Pharmaceutical Co., Ltd provides.
(2) lot number: DM03250
4, animal:
Source, kind, the quality certification: 4 of female sd inbred rats are provided by Chinese Academy of Sciences's Shanghai Experimental Animal Center.The quality certification: No. the 005th, the moving pipe of middle section.Test adaptability the last week is raised.Feedstuff is available from west, the joint Shanghai of China and Britain pul-Bi Kai laboratory animal company limited.Freely fetch water, ingest, raising temperature is 23 ± 2 ℃.
5, dosage
(1) dosage setting: clinical human vagina lactobacillus effervescent tablet 10
6CFU/ sheet/people (1g/ sheet).The effective dose of animal is 10
6The CFU/ sheet/only.Be observation toxic reaction big as far as possible dosage and the technical relation of considering film-making.If 1.7 * 10
7The CFU/ sheet/only with 6.9 * 10
9The CFU/ sheet/only.Calculate respectively quite clinical consumption 10 and 1000 times by local application amount, and establish excipient and untreated fish group.
(2) every animals received capacity: 1/only.
6, route of administration;
The rat vagina administration.
7, method
Earlier use the physiologic dose brine washing vagina during test, will be tried thing then and insert in the rat vagina gently.Examine 6 hours and guarantee that tablet contacts with vaginal mucosa looking on.Promptly observe the reaction of animals situation after the administration,, check internal organs if dead animal is promptly dissected.
8, observation index:
(1) observation period: 14 days
(2) toxic reaction: situations such as observation and inspection rat outward appearance, behavior, feed, feces, body weight gain, dead animal becomes celestial.When experiment finished in the 15th day, survival rats was dissected, and checked organ diseases such as the heart, lung, liver,spleen,kidney.
9, result:
After rat vagina awarded the lactobacillus effervescent tablet, situations such as outward appearance behavior, feed and feces there is no ANOMALOUS VARIATIONS, no animal dead, and it is similar to untreated fish group with vehicle group that rat body weight increases the administration group.The body weight gain situation is listed following table in:
The influence of lactobacillus effervescent tablet of table six, vagina to rat body weight
| Time (my god) | Untreated fish group body weight (g) | Excipient body weight (g) | 0.25 * 107CFU/g/ body weight (g) | 0.25 * 109CFU/g/ body weight (g) |
| D0 D2 D4 D6 D8 D10 D12 D14 | 219.7±11.1 221.8±13.7 224.9±14.1 230.4±12.9 231.2±13.0 233.2±9.96 235.2±9.66 238.7±10.1 | 220.2±8.2 223.9±7.1 229.2±6.2 237.3±8.6 240.4±11.1 246.7±14.4 250.6±14.6 253.0±14.5 | 220.0±8.9 228.8±5.3 236.3±7.3 247.9±8.7 250.9±7.8 259.1±8.7 259.5±10.7 260.9±10.8 | 219.3±7.7 223.4±8.9 232.8±11.7 244.5±12.8 250.5±14.2 255.5±14.2 251.0±16.3 254.3±15.5 |
10, evaluation of result:
It is clinical consumption 10 or 1000 times that effervescent tablet, contained antibacterial are used in experiment.Much smaller because of rat volume ratio people, dwindle so the size of effervescent tablet is also corresponding, contain the nectar degree comparatively speaking and want high than the human effervescent tablet.Reached capacity from tabletting technology.Rat vagina awards lactobacillus effervescent tablet 1.7 * 10
7, 6.9 * 10
9CFU/ sheet/only, observed continuously 14 days, activities in rats is normal after the administration, and Non Apparent Abnormality changes, no animal dead.The administration group increases with the vehicle group rat body weight and shows that processed group is similar.Rat vagina uses the maximum tolerated dose of lactobacillus effervescent tablet greater than 6.9 * 10
9CFU/ only.
Five, bacillus acidophilus SL 9404 strain stability tests (measuring) by Nat'l Pharmaceutical ﹠ Biological Products Control Institute
1, purpose: observe the stability after bacillus acidophilus SL 9404 involves continuous 30 generations of going down to posterity in a criminal case.
2, materials and methods:
(1) bacterial strain: bacillus acidophilus SL 9404 strains are provided by friendship Pharma Inc. of last Hisense.
(2) culture medium:
1. the MRS fluid medium-usefulness goes down to posterity
2. MRS agar culture medium-flag check is used
3. sugared biochemical reaction culture medium-observation biochemical reaction is used
4. PYG fluid medium-survey metabolite is used
(3) method:
Strain carries out former generation strain and the strain of 30 generations the comparison of phenotypic characteristic biology (comprising lactic acid content mensuration in growth characteristics, colonial morphology, dyeing microscopic examination, biochemical reaction, drug sensitive test, toxicity test and the metabolite) and hereditism's feature (G+C Mol% mensuration) by after 30 generations of MRS fluid medium continuous passage.
3, result:
It is 7 listed that former generation strain and 30 generations strain characteristic check see Table.
Table 7 bacillus acidophilus 9404 former generation strains and 30 stable comparisons of feature in generation
| Inspection item | 9404 strains (former generation) | 9404 strains (30 generation) |
| Growth characteristics | (1) all can grow in the aerobic or anaerobic environment (2) on MRS agar, be grown to light yellow, the about 0.5-1mm of the circular colony diameter of central protrusion. | (1) all can grow in the aerobic or anaerobic environment (2) on MRS agar, be grown to light yellow, the about 0.5-1mm of the circular colony diameter of central protrusion. |
| Dyeing microscopic examination | The Gram-positive thalline is quarter butt shape, is dispersed in or in pairs, becomes short chain to arrange.The about 0.5-0.8 μ m of thalline size * 1.5-3 μ m | The Gram-positive thalline is quarter butt shape, is dispersed in or in pairs, becomes short chain to arrange.The about 0.5-0.8 μ m of thalline size * 1-2.5 μ m |
| Biochemical reaction | The sweet fruit half sugarcane Mai Lali grape in A Mu Mus nuclear Portugal reveal newborn bud uncle sugar sugar sugar sugar sugar sugar sugar sugar sugar sugar---+++++++ | The sweet fruit half sugarcane Mai Lali grape in A Mu Mus nuclear Portugal reveal newborn bud uncle sugar sugar sugar sugar sugar sugar sugar sugar sugar sugar---+++++++ |
| The cotton pine of fine newborn gill fungus honey can form sediment the pure glycosides sugar of sweet mountain 7 degree of freedom two sons, three molten dew Folium pyri disaccharide sugar sugar powder sugar sugared+++--+-+++ | The cotton pine of fine newborn gill fungus honey can form sediment the pure glycosides sugar of sweet mountain 7 degree of freedom two sons, three molten dew Folium pyri disaccharide sugar sugar powder sugar sugared+++--+-+++ | |
| The bright nitre of water also cattle touch the plain liquid salt of poplar glue yoghourt former coagulate change solid enzyme+--+- | The bright nitre of water also cattle touch the plain liquid salt of poplar glue yoghourt former coagulate change solid enzyme+--+- | |
| Drug sensitive test | Amikacin R tetracycline S gentamicin R erythromycin S streptomysin R PB R neomycin R chloramphenicol S ampicillin S furazolidone R closes spore azoles quinoline S SMZco R cefuroxime S orfloxacin R | Amikacin R tetracycline S gentamicin R erythromycin S streptomysin R PB R neomycin R chloramphenicol S ampicillin S furazolidone R closes spore azoles quinoline S SMZco R cefuroxime S orfloxacin R |
| Toxicity test | Mouse peritoneal injection 1.0 * 10 9Behind the CFU viable bacteria, mice is strong deposits weight increase. | |
| The metabolite organic acid is measured | Lactic acid 0.5331% acetic acid 0.0796% | Lactic acid 0.5482% acetic acid 0.0600% |
| G+CMol% | 39.76 | 39.76 |
Conclusion: in 30 generations of 9404 strain continuous passages, biology and genetics characteristic are stable.
9403,9405 strain bios are learned, hereditism's feature compares
| Inspection item | 9403 | 9405 |
| Growth characteristics | (1) all can grow in the aerobic or anaerobic environment (2) on MRS agar, be grown to ecru, circle, projection smooth colony 1-2mm size. | (1) all can grow in the aerobic or anaerobic environment (2) on MRS agar, be grown to light yellow, the about 0.5-1mm of the circular bacterium colony of central protrusion size. |
| Dyeing microscopic examination | The Gram-positive thalline is quarter butt shape, about 0.3-0.5 μ m * 1-1.5 μ m. | The Gram-positive thalline is quarter butt shape, about 0.5-0.8 μ m * 1-2.5 μ m |
| Biochemical reaction | The sweet fruit half sugarcane Mai Lali grape in A Mu Mus nuclear Portugal reveal newborn bud uncle sugar sugar sugar sugar sugar sugar sugar sugar sugar sugar--±+++++++ | The sweet fruit half sugarcane Mai Lali grape in A Mu Mus nuclear Portugal reveal newborn bud uncle sugar sugar sugar sugar sugar sugar sugar sugar sugar sugar+-++++++++ |
| The cotton pine of fine newborn gill fungus honey can form sediment the pure glycosides sugar of sweet mountain 7 degree of freedom two sons, three molten dew Folium pyri disaccharide sugar sugar powder sugar sugared+++--+-+++ | The cotton pine of fine newborn gill fungus honey can form sediment the pure glycosides sugar of sweet mountain 7 degree of freedom two sons, three molten dew Folium pyri disaccharide sugar sugar powder sugar sugared+-++-+-+++ | |
| The bright nitre of water also stone touch the plain liquid salt of poplar glue acid stamen aurochsization milk enzyme+--+- | The bright nitre of water also cattle touch the plain liquid salt of poplar glue yoghourt former coagulate change solid enzyme+--+- | |
| Drug sensitive test | Amikacin R tetracycline S gentamicin S erythromycin S streptomysin S PB R neomycin R chloramphenicol S ampicillin S furazolidone R closes spore azoles quinoline S SMZco R cefuroxime S orfloxacin R | Amikacin R tetracycline S gentamicin R erythromycin S streptomysin R PB R neomycin R chloramphenicol S ampicillin S furazolidone R closes spore azoles quinoline S SMZco S cefuroxime S orfloxacin R |
| The metabolite organic acid is measured | Lactic acid 0.9106% acetic acid 0.0560% | Lactic acid 0.6884% acetic acid 0.1115% |
| G+CMol% | 41.84 | 42.88 |
Conclusion:
(1) two strain bacteria growing feature, colonial morphology and dyeing microscopic examination meet the lactobacillus feature.
(2) two strain bacterium all can produce lactic acid.
(3) 9403 strain ribose, melezitose, mannitol, sorbitol biochemical reaction do not meet bacillus acidophilus's feature of uncle Jie Shi handbook regulation.
9405 strain arabinose, ribose, melezitose, mannitol biochemical reaction do not meet bacillus acidophilus's feature of uncle Jie Shi handbook regulation.
The G+C Mol% measured value of the DNA of (4) two strain bacterium is higher than the G+C Mol% content of the heavy breathing Lactobacillus lactis of uncle Jie Shi handbook regulation.
It is the common disease of women that woman vagina infects, and is that microecological balance imbalance institute causes disease in the woman vagina, and main and sex hormone level, sexual life are excessively, peace intrauterine device and antibacterial therapy upset vagina normal flora etc. are relevant.The ratio that the woman vagina incidence of infection accounts in the female diseases is higher, by replenishing the vagina probiotic bacteria, make probiotic bacteria field planting in vagina, thereby stop the procreation of antibacterial in the vagina, play colpitic effect of treatment and effect, alleviate and free women's sufferings.The present invention has great economic efficient latent and high exploitation is worth.
Example one bacillus acidophilus is to the obvious adhesion of human vagina's epithelial cell (VEC)
By this test, tested bacillus acidophilus SL9404 to the epithelial adhesive capacity of human vagina.
Get each 1ml of human vagina's epithelial cell suspension and bacteria suspension, mix, 37 ℃, cultivated in 2 hours; Smear, drying at room temperature, methanol is 10min fixedly, and Gram, mirror are observed antibacterial adhesion situation and counting on human vagina's epithelial cell down.
The result who obtains represents in Table 1, shows that bacillus acidophilus SL9404 has very strong adhesive capacity to human vagina's epithelial cell, is suitable for preparing preparation of the present invention.
Table one bacillus acidophilus SL9404 strain is to the adhesive attraction of VEC
| The VEC numbering | The adhesion bacterial population (individual/VEC) | The VEC numbering | The adhesion bacterial population (individual/VEC) | The VEC numbering | The adhesion bacterial population (individual/VEC) |
| 1 | 132 | 18 | 92 | 35 | 85 |
| 2 | 113 | 19 | 120 | 36 | 123 |
| 3 | 74 | 20 | 89 | 37 | 144 |
| 4 | 149 | 21 | 65 | 38 | 131 |
| 5 | 186 | 22 | 78 | 39 | 156 |
| 6 | 118 | 23 | 158 | 40 | 98 |
| 7 | 111 | 24 | 75 | 41 | 143 |
| 8 | 63 | 25 | 126 | 42 | 125 |
| 9 | 84 | 26 | 118 | 43 | 95 |
| 10 | 89 | 27 | 109 | 44 | 194 |
| 11 | 94 | 28 | 138 | 45 | 88 |
| 12 | 118 | 29 | 80 | 46 | 155 |
| 13 | 119 | 30 | 128 | 47 | 178 |
| 14 | 125 | 31 | 74 | 48 | 122 |
| 15 | 90 | 32 | 77 | 49 | 167 |
| 16 | 120 | 33 | 50 | 50 | 133 |
| 17 | 129 | 34 | 62 | X±S | 113.8±33.69 |
Example two bacillus acidophilus' Chinese People's Anti-Japanese Military and Political College enterobacteria and Candida albicans effect
Bacillus acidophilus SL9404 disturbs escherichia coli and Candida albicans to obtain check in the epithelial adherent ability of human vagina with competitive way.
Get 1ml Escherichia coli bacteria liquid or 1ml Candida albicans bacterium liquid and 1ml VEC suspension mixing earlier, behind 37 ℃ of pre-cultivation 30min, add 1ml lactobacillus bacterium liquid again, mixing continues 37 ℃, 2 hours, observes down and counting by above-mentioned example one test method mirror.
The result who obtains represents in table two, shows that bacillus acidophilus SL9404 has reduced escherichia coli and Candida albicans in the epithelial adhesion of human vagina.
Table two bacillus acidophilus SL9404 strain influences at the VEC adhesive attraction escherichia coli 44113 or Candida albicans 10231
| Bacterial strain | Escherichia coli 44113 adhesion number/VEC (X ± S) | Candida albicans 10231 adhesion number/VEC (X ± S) | Statistical disposition |
| Escherichia coli 44113 | 180.7±252.20 | P＜0.01 | |
| Escherichia coli 44113+bacillus acidophilus SL9404 | 134.18±40.63 | ||
| Candida albicans 10231 | 29.24±8.85 | 0.01＜P＜0.05 | |
| Candida albicans 10231+bacillus acidophilus SL9404 | 24.40±11.36 |
Example three bacillus acidophilus are in external inhibition to gonococcus, escherichia coli, albicans growth
Bacillus acidophilus bacterium liquid constitutes test group with three kinds of pathogenic bacterium bacterium liquid mixed in equal amounts in triangular flask (9ml+9ml) respectively.Every kind of bacterium liquid mixes the formation matched group with equivalent 2% calf serum TPY culture fluid (9ml+9ml) simultaneously.Test group and matched group all place 37 ℃ of water-baths to be cultured to 72 hours or 96 hours.Each test group, matched group are being cultivated initial (0 hour), each sampling in 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, bacillus acidophilus in the determination test group triangular flask and the bacterial growth concentration of three kinds of pathogenic bacterium respectively.Also measure simultaneously the bacterium amount of each matched group.
The result who obtains represents in table three, shows that bacillus acidophilus SL9404 can comparatively fast suppress in external growth to gonococcus, also can suppress the growth of Escherichia coli, and Candida albicans is also had certain effect.
Table three bacillus acidophilus SL9404 strain antagonistic effect result
| Group | Viable count (CFU/ml) the Log value of different incubation times | ||||||
| 0 hour | 12 hours | 24 hours | 48 hours | 72 hours | 96 hours | ||
| Test group | SL9404+gonococcus 29403 | 5.9165 3.3979 | 8.3502 3.8692 | 8.8209 ＜1 | 8.4983 ＜1 | 8.0253 ＜1 | |
| SL9404+escherichia coli 44113 | 5.9165 3.7782 | 8.2577 8.8727 | 8.8395 8.7404 | 8.9004 ＜5 | 8.7308 ＜1 | ||
| SL9404+Candida albicans 10231 | 5.9165 3.7782 | 8.3201 7.6821 | 8.5775 7.8420 | 8.7745 7.7474 | 8.8028 7.8921 | 8.7559 7.9731 | |
| Matched group | Gonococcus 29403 | 3.3979 | 3.8865 | 3.6990 | ＜1 | ＜1 | |
| Escherichia coli 44113 | 3.7782 | 8.8882 | 8.8176 | 8.8987 | 8.4409 | ||
| Candida albicans 10231 | 3.7782 | 7.8481 | 8.1614 | 8.1903 | 8.4314 | 8.2041 | |
| Bacillus acidophilus SL9404 | 5.9165 | 8.4100 | 8.7752 | 8.2455 | 7.8722 | 7.1303 | |
Example four freeze-dried Lactobacillus acidophilus powders warp and excipient composition, preparation forms the prescription of tablet.
| The lyophilizing mycopowder | 100mg |
| Microcrystalline Cellulose | 500mg |
| Lactose | 320mg |
| Carboxymethyl starch sodium | 50mg |
| Magnesium stearate | 20mg |
| Colloidization silicon dioxide | 10mg |
Above-mentioned material needed 40 mesh sieves before the tabletting, and after fully mixing, in rotary tablet machine, was pressed into tablet with oval punch die, and sheet heavily is the tablet,vaginal of 1000mg.This film can soften within several minutes.
Example five freeze-dried Lactobacillus acidophilus powders warp and weak acid and carbonate formulation, preparation becomes the prescription of vagina effervescence.
| The lyophilizing mycopowder | 100mg |
| Tartaric acid | 400mg |
| Sodium bicarbonate | 80mg |
| Calcium carbonate | 60mg |
| Microcrystalline Cellulose | 200mg |
| Lactose | 120mg |
| Colloidization silicon dioxide | 10mg |
| Magnesium stearate | 20mg |
| Hypromellose | 10mg |
When preparing above-mentioned tablet, sodium bicarbonate and calcium carbonate need be made granule in advance, in rotary tablet machine, are pressed into tablet,vaginal with oval punch die, and sheet heavily is 1000mg.Through the gas release inspection, the result in 2ml water 20 minutes gas releases greater than 6ml, less than 10ml.
Example six
| The lyophilizing mycopowder | 500mg (in two aluminium foil small package bags) |
| Physiological saline solution | 10ml (in little plastic bottle) |
The lyophilizing mycopowder is loaded in the aluminium foil pouch, in addition physiological saline solution is loaded in the plastic jar.During use the lyophilizing mycopowder is poured in the above-mentioned plastic jar, used behind the mixing
Example seven vagina ointment (5g pipe)
| The lyophilizing mycopowder | 500mg |
| Lanoline | 1g |
| Vaseline | 1g |
| Colloidization silicon dioxide | 2.5g |
Lanoline, vaseline are preheating to 35-42 ℃, make whole thawings, add colloidization silicon dioxide and lyophilizing mycopowder again and stir, make evenly, in the flexible pipe of packing into.
The preparation of example eight lactobacillus sprays (10g)
| The lyophilizing mycopowder | 100mg |
| PVP | 500mg |
| Physiological saline solution | 10 |
| Carbon dioxide | In right amount |
When preparing above-mentioned spray, earlier with the lyophilizing mycopowder, PVP and physiological saline solution are mixed with suspension, pour in the spray special-purpose bottle, with spray nozzle specially used airtight after, pour into carbon dioxide.
Claims (3)
1, a kind of pharmaceutical preparation that contains the bacillus acidophilus, it is characterized in that said preparation is made up of the bacillus acidophilus and the pharmaceutical excipient of separation and purification from vaginal secretions, wherein, described strain is numbered the bacillus acidophilus SL9404 of CCTCC NO:M200013 for being preserved in Chinese typical culture collection center.
2, a kind of a kind of preparation method that contains bacillus acidophilus's pharmaceutical preparation as claimed in claim 1 is characterized in that this method comprises the following steps:
(1) bacillus acidophilus's mycopowder of preparation separation and purification from vaginal secretions:
The bacillus acidophilus SL9404 bacterial strain that secretions in the vagina is separated, obtains behind the purification is rule on the MRS agar slant and is gone down to posterity, and cultivates 48h through 37 ± 1 ℃; Choose full, color and luster is even, medium bacterium colony bigger than normal, once more on the MRS agar slant of streak inoculation in the Fructus Solani melongenae bottle, cultivates 48h through 37 ± 1 ℃; Transferred species inserts beef cysticercosis cellulosae cutis pipe, cultivates 20-50h for 37 ± 1 ℃; Get 1-4 and prop up the cysticercosis cellulosae cutis pipe and change 300ml milk fermentation culture medium or 5-20% Tomato juice fermentation medium or milk+Tomato juice's fermentation medium over to, cultivate the 8-48h fermentation culture for 37 ± 1 ℃, progressively be amplified to bulk fermentation, centrifugal, make mycopowder after the lyophilization;
(2) preparation medicament:
Take by weighing bacillus acidophilus and pharmaceutical excipient by the treatment effective dose, drug formulation process is made various preparations routinely.
3, a kind of pharmaceutical preparation that contains the bacillus acidophilus according to claim 1 is characterized in that said preparation is liquid form, mastic form or solid form, tablet, capsule, powder, cream, ointment, suppository or spray.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001254693A CN1234373C (en) | 2000-09-28 | 2000-09-28 | Medicinal preparation containing lactobacillus acidophilus and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001254693A CN1234373C (en) | 2000-09-28 | 2000-09-28 | Medicinal preparation containing lactobacillus acidophilus and preparation process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1345589A CN1345589A (en) | 2002-04-24 |
| CN1234373C true CN1234373C (en) | 2006-01-04 |
Family
ID=4591257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001254693A Expired - Fee Related CN1234373C (en) | 2000-09-28 | 2000-09-28 | Medicinal preparation containing lactobacillus acidophilus and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1234373C (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK286263B6 (en) * | 2004-07-16 | 2008-06-06 | Výskumný Ústav Chemických Vlákien, A. S. | Additive concentrates for thermo stabilization of polyamide fibres |
| IT1403661B1 (en) * | 2011-01-28 | 2013-10-31 | Probiotical Spa | EFFERVESCENT COMPOSITION IN THE SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONS. |
| ITMI20110793A1 (en) | 2011-05-09 | 2012-11-10 | Probiotical Spa | STRAINS OF PROBIOTIC BACTERIA AND SYNBIOTIC COMPOSITION CONTAINING THEMSELVES INTENDED FOR THE BABY FOOD. |
| ITMI20110792A1 (en) | 2011-05-09 | 2012-11-10 | Probiotical Spa | STRAINS OF BACTERIA BELONGING TO THE BIFIDOBACTERIUM TYPE FOR USE IN THE TREATMENT OF HYPERCOLESTEROLEMIA. |
| ITMI20110791A1 (en) | 2011-05-09 | 2012-11-10 | Probiotical Spa | BACTERIA OF BACTERIA ABLE TO METABOLIZE THE OXALATES. |
| ITRM20110477A1 (en) | 2011-09-09 | 2013-03-10 | Giovanni Mogna | COMPOSITION INCLUDING N-ACETYLCISTEIN AND / OR LYSOZYME MICROINCAPSULATE GASTROPROTECT IN ASSOCIATION WITH PROBIOTIC BACTERES ABLE TO RESTORE THE BARRIER EFFECT OF THE STOMACH THAT IS LOST DURING THE PHARMACOLOGICAL TREATMENT OF |
| ITMI20111718A1 (en) | 2011-09-23 | 2013-03-24 | Probiotical Spa | A WATERPROOF MOISTURE AND OXYGEN MATERIAL FOR PACKAGING DIETARY, COSMETIC AND MEDICINAL PRODUCTS. |
| ITMI20130793A1 (en) | 2013-05-14 | 2014-11-15 | Probiotical Spa | COMPOSITION INCLUDING LACTIC BACTERIA FOR USE IN THE PREVENTIVE AND / OR CURATIVE TREATMENT OF THE RECURRENT CYCLES. |
| CN103695442B (en) * | 2013-12-13 | 2016-01-20 | 上海市农业科学院 | A kind of NFSAI gene coming from Lactobacterium acidophilum and its preparation method and application |
| CN107714672B (en) * | 2017-09-11 | 2019-08-06 | 广州市微生物研究所 | A kind of woman's vagina active probiotic gel packing and preparation method thereof |
| CN114591875B (en) * | 2022-05-07 | 2022-07-29 | 微康益生菌(苏州)股份有限公司 | Lactobacillus acidophilus LA88 for improving vaginal environment and culture method and application thereof |
-
2000
- 2000-09-28 CN CNB001254693A patent/CN1234373C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1345589A (en) | 2002-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11980660B2 (en) | Edible vaccination against microbial pathogens | |
| CN1308436C (en) | Lactic acid producing bacteria for use as probiotic organisms in the human vagina | |
| TWI652343B (en) | Lactobacillus crimper (LACTOBACILLUS Crispatus) and application thereof | |
| CN1342196A (en) | Bifidobacterium in treatment of inflammatory disease | |
| CN1234373C (en) | Medicinal preparation containing lactobacillus acidophilus and preparation process thereof | |
| Huicab-Pech et al. | Pathogenic bacteria in Oreochromis niloticus var. Stirling tilapia culture | |
| CN1057563C (en) | Bacterial stain of bacillus subtilis and application thereof | |
| CN116083273B (en) | Lactobacillus plantarum NHE-LpE and application thereof | |
| WO2016046706A1 (en) | Probiotic fermented feed additives | |
| CN115851494A (en) | Lactobacillus plantarum NHE-LpE and application thereof | |
| CN115287224A (en) | Yak-derived lactobacillus reuteri for improving intestinal microbial development of indigenous animals and application thereof | |
| KR102130646B1 (en) | Novel lactobacillus salivarius and feed additives for aquacultural fish and crustacea comprising the same | |
| CN109652334A (en) | A kind of complex microbial inoculum and its preparation method and application | |
| CN109486732A (en) | A kind of bifidobacterium longum and its application | |
| CN116004430B (en) | Lactobacillus plantarum NHE-LpE9 and application thereof | |
| CN1059235C (en) | Preparation of living bacillus subtilis and preparation method thereof | |
| CN101067120A (en) | Fecal enterococcus CMS-II001 and its application | |
| CN1391905A (en) | Microbial preparation for curing intestinal diseases | |
| JP2006158396A (en) | Novel lactic acid bacterium strain for producing cactus lactic acid fermentation product and method for producing cactus fermentation product by using the same | |
| CN1546064A (en) | Freeze dried microecologic preparation for preventing and treating gallinaceous white dysentery | |
| CN109517765A (en) | A kind of streptococcus fecalis and its application | |
| CN112940998B (en) | Bacterial strain for preventing bacterial diseases and application | |
| CN113604400B (en) | Novel lactobacillus YUYINGW with diabetes preventing or treating effect | |
| Braide et al. | The effects of Lactobacillus acidophilus (Probiotics) and other fungicidal agents against vagina Candida albicans | |
| Cheng et al. | Effects of temperature on growth, feed intake and antithrombin activity of Poecilobdella manillensis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| ASS | Succession or assignment of patent right |
Owner name: XINYI PHARMACEUTICAL FACTORY Free format text: FORMER OWNER: SHANGHAI XINYI PHARMACEUTICAL CO., LTD. Effective date: 20040917 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20040917 Address after: 201206 No. 905 Jinqiao Road, Shanghai Applicant after: Sine Pharmaceutical Factory Co., Ltd. Address before: 201206, Jinqiao new Jinqiao Road 905, Shanghai, Pudong Applicant before: Xinyi Pharmaceutic Co., Ltd., Shanghai |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SHANGHAI SINE PHARMACEUTICAL FACTORY CO., LTD. Free format text: FORMER NAME: SINE PHARMACY FACTORY |
|
| CP03 | Change of name, title or address |
Address after: No. 905 Jinqiao Road, Shanghai, Pudong New Area Patentee after: Shanghai Sine Pharmaceutical Co., Ltd. Address before: No. 905 Jinqiao Road, Shanghai Patentee before: Sine Pharmaceutical Factory Co., Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 201206 Pudong New Area new Jinqiao Road, Shanghai, No. 905 Patentee after: Shanghai Xinyi Pharmaceutical Co. Ltd.. Address before: 201206 Pudong New Area new Jinqiao Road, Shanghai, No. 905 Patentee before: Shanghai Sine Pharmaceutical Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060104 Termination date: 20190928 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |